Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of CY-101 in adrenocortical carcinoma
ISRCTN15479264Phase 2Recruiting
- Sponsor
- Cancer Research UK
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
Phase 2, randomised, open-label trial of cypep-1 in adrenal cancer (ACC) (3 arms), sponsored by Cancer Research UK. Primary endpoints: Optimal dose determination and Overall response rate by itRECIST. Started Mar 2026; status: recruiting.
02
Drugs
cypep-1
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on ISRCTN15479264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15479264.